about
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.Probiotics in infective diarrhoea and inflammatory bowel diseases.Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.Management of pouch dysfunction or pouchitis with an ileoanal pouch.Short-term treatment with infliximab in chronic refractory pouchitis and ileitis.Role of conventional therapies in the era of biological treatment in Crohn's disease.Absence of change in the gray matter volume of patients with ulcerative colitis in remission: a voxel based morphometry study.Diagnosis and treatment of pouchitis.Probiotics for the treatment of postoperative complications following intestinal surgery.Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease.Infliximab in the treatment of Crohn's disease.Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis.Management of inflammatory bowel disease: does rifaximin offer any promise?Probiotics and barrier function in colitis.VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics.Antimicrobials in the management of inflammatory bowel disease.Review article: aminosalicylates for distal colitis.Eviendep® reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosisThe role of Budesonide-MMX in active ulcerative colitis.Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression.Distinct proteomic profiles characterise non-erosive from erosive reflux disease.The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis.Loss of miR-101 expression promotes Wnt/β-catenin signalling pathway activation and malignancy in colon cancer cells.Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production.Medical treatment and management of severe ulcerative colitis.The effect of transient intestinal ischemia on inflammatory parameters.Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach.Parvovirus b19 infection localized in the intestinal mucosa and associated with severe inflammatory bowel disease.High-dose probiotics for the treatment of active pouchitis.Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD).Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls.Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon.Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study.
P50
Q30581062-46A96758-0FE3-41CA-A653-8489911E8BF0Q30778152-6460CFB0-E6A4-4914-AD4E-C3142E6CD5B1Q33231186-EB62C248-04AF-4BBF-B82F-779AE67ABB6BQ33939743-DF9887C0-DA50-4855-8762-AFAD8E7969A2Q34504027-2674FCF9-681F-4B43-A772-DAFD97ED800CQ34551989-C12A1428-E4CA-4C9B-90C8-99036BF49E9CQ34588754-E262F10A-E1BB-4B06-95A6-4235785129B4Q34831072-0CD3FA14-2E74-45A4-B8E8-8DE07D3E034FQ34998108-56D28DB4-9874-4C1F-96D7-3BA268D3C1CBQ35078337-CE24FE57-6674-473B-BA77-0A8185B3FCF4Q35542640-BFBBA34B-276D-49E5-BB62-0F1508F07DD0Q35555687-363F8845-8C60-4B86-B5DF-B4B2BA5F8CFCQ35919228-0D81FA4B-C93F-4E7C-89D5-10C9D0881910Q36045296-83EC998B-EAE9-4D76-8B10-9E78B0FC71C3Q36108499-83C07721-E974-4D3A-93AA-958FF52F79E4Q36160698-06D688AE-7B83-4B09-9B41-74E4581E4046Q36220440-7E8CB3EC-7468-40D8-994E-CA2C996A4D22Q36404946-F0F5837E-92B5-4391-981B-E76E953367D3Q36589416-D9FC4F43-196D-4D9B-8690-FC804CC542B7Q37162458-84FB856A-9BA7-4DD1-811C-42602589E24DQ38185703-D055A78B-69E5-46D7-B237-44DB8321CE99Q38442953-49CE0A04-F64C-493A-AE28-B75A1CBB4E99Q38501133-40A5F49E-5277-4521-BE5A-143AB62C17BEQ38552422-961B20B4-97F3-4FC7-ACAA-1E3F5BEBD69FQ39289136-9F046B2E-B3E6-4D19-A5A7-BA480DD7F324Q39666493-3F5AA9BF-58D3-4869-8F2D-2D59AB1FC733Q39975422-EC2AF8CE-A15A-455F-855D-8E6644697FF4Q40415198-6E3A965A-554D-4AEC-B86B-3BF88CD939C0Q42528303-43CC14B0-0A32-4556-BA70-C350531DBEE3Q42674728-4915847B-625A-4D05-AE73-4C02F0290A12Q42945261-5E4C726B-7972-4C94-98D9-11A1513D730CQ43127800-ED9313EA-E5F9-4F43-B2FF-AD3A19F59BA1Q43353488-9AE4410B-2BEE-44D7-B62A-9C9F50CF1670Q43363077-4590BAA2-F518-4DAE-AACB-6FC18A92C82DQ43407161-5D8F1A7B-0EFF-467D-BB28-980C2274F7D5Q43606551-5CF1E5F5-5178-4160-B86C-58FF2B853825Q43659057-A2D765B4-B456-4DED-8E3E-0B1A70AC4750Q43816718-C7830250-006B-4305-B537-9BF91B1C2AB9Q44006203-307CD4E5-DF26-4CCA-A499-7B1188BEF795Q44488900-6B0767F7-40DF-44E9-9F02-C0F16A339359
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
F Rizzello
@ast
F Rizzello
@en
F Rizzello
@es
F Rizzello
@nl
F Rizzello
@sl
type
label
F Rizzello
@ast
F Rizzello
@en
F Rizzello
@es
F Rizzello
@nl
F Rizzello
@sl
prefLabel
F Rizzello
@ast
F Rizzello
@en
F Rizzello
@es
F Rizzello
@nl
F Rizzello
@sl
P106
P1153
7003296092
P31
P496
0000-0002-7949-5362